Legend Biotech Corporation announced its first quarter 2025 financial results, reporting CARVYKTI® (ciltacabtagene autoleucel) net sales of approximately $369 million with over 6,000 patients treated ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion. The life science giant reported adjusted ...

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year. Aided by a rebound in ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

The biotech industry has delivered an upbeat performance so far in 2026 despite an uncertain macroeconomic backdrop. Strong ...